



KOLINPHARMA®  
LEADER TO HEALTH



## KOLINPHARMA: PUBLICATION NOTICE OF CONVOCAATION OF THE ORDINARY ASSEMBLY

*Milan, April 12<sup>nd</sup> 2018*

The Shareholders of Kolinpharma S.p.A. are convened in the Ordinary Shareholders' Meeting at the headquarters in Lainate Corso Europa n. 5, on first call on April 30th 2018 at 3:00 pm and on second call on May 8th 2018 at 3:00 pm, to deliberate on the following agenda:

**Single Object:** Statutory Financial Statements at December 31, 2017 of Kolinpharma SpA, reports of the Board of Directors on Operations, of the Independent Auditors and of the Board of Statutory Auditors. Related and consequent resolutions.

### **Composition of the share capital and voting rights**

The share capital of Kolinpharma S.p.A. equal to 1,639,571 euros, is made up of n. 1,639,571 shares with no par value, of which n. 1,459,571 are ordinary shares and no. 180,000 are Price Adjustment Shares. Each share has the right to one vote.

### **Participation in the Assembly and exercise of rights**

Each shareholder may be represented at the meeting by written proxy, also conferred on a non-shareholder, subject to incompatibilities and the limits established by law.

The entitlement to participate in the meeting and the exercise of the right to vote is attested by a communication to the Company made by an intermediary authorized to record the accounts on which the shares are registered pursuant to the law, in accordance with their accounting records, in favor of the subject with the right to vote (the "Communication"). The Communication is made on the basis of the evidence relating to the end of the accounting day of the seventh (seventh) open

KOLINPHARMA S.p.A.  
SEDE OPERATIVA  
Corso Europa, 5  
20020 Lainate (MI)  
Tel. +39 02 94324300  
Fax +39 02 93571446

SEDE LEGALE  
Via Larga, 8  
20122 Milano

info@kolinpharma.com  
C.F. e P. IVA 08331990963  
Cap. soc. € 1.639.571 i.v.  
R.E.A. MI-2018304

[www.kolinpharma.com](http://www.kolinpharma.com)





KOLINPHARMA®

LEADER TO HEALTH

market day preceding the date set for the meeting in first call. The credit or debit entries made on the accounts after this deadline are not relevant to the exercise of voting rights in the shareholders' meeting.

The Communication made by the authorized intermediary must be received by the Company by the end of the third (third) day of the open market preceding the date set for the meeting in first call; the right to intervene and exercise the right to vote remains valid if the Communication has been received by the Company beyond the aforementioned deadlines, provided that the meeting is closed by the single call.

Unless otherwise indicated, the intervention and the vote are regulated by law.

## Documentation

The documentation relating to the agenda of the Shareholders' Meeting, as required by current legislation and regulations, will be made available to the public in accordance with the law and regulations at the registered office and will also be published on the Company's website:

[www.kolinpharma.com](http://www.kolinpharma.com)> Investor Relations> Shareholders' Meetings. Shareholders have the right to review them and obtain copies at their own expense. This notice will be published in the "Italia Oggi" newspaper of April 13, 2018 and on the Company's website.

*This press release is available online on our corporate website [www.kolinpharma.com](http://www.kolinpharma.com), in the section Investor Relations > Financial Press Releases.*

\*\*\*

*KOLINPHARMA® S.p.A., founded in 2013, is an Innovative SME operating in nutraceutical sector and specialised in the research and development, realised internally and in collaboration with the major Italian universities. The Company's products are made of innovative and natural raw materials and have the purpose of supporting the pharmacological treatments mainly for the diseases in the orthopaedic-physiatric and gynaecological fields. KOLINPHARMA distributes the products with its brand in the whole Italian territory through a skilled sales network of 63 medical-scientific representatives (MSRs), specialised sole agents graduated in scientific disciplines. The MSRs promote KOLINPHARMA's nutraceutical products directly to doctors, pointing at the specialists' awareness. The Company's direct clients are wholesalers, that distribute to pharmacies and para-pharmacies throughout Italy. KOLINPHARMA owns 4 patents in Italy and 9 certifications, of which 2 on the company and 7 on its products.*

## Contacts

KOLINPHARMA S.p.A.  
SEDE OPERATIVA  
Corso Europa, 5  
20020 Lainate (MI)  
Tel. +39 02 94324300  
Fax +39 02 93571446

SEDE LEGALE  
Via Larga, 8  
20122 Milano

info@kolinpharma.com  
C.F. e P. IVA 08331990963  
Cap. soc. € 1.639.571 i.v.  
R.E.A. MI-2018304

[www.kolinpharma.com](http://www.kolinpharma.com)





**KOLINPHARMA®**

LEADER TO HEALTH



**IR TOP Consulting S.r.l.**

**Capital Markets & Investor Relations**

Floriana Vitale, Domenico Gentile

[f.vitale@irtop.com](mailto:f.vitale@irtop.com), [d.gentile@irtop.com](mailto:d.gentile@irtop.com)

Via C. Cantù, 1 - 20123 Milan

Tel.: +39 02 4547 3883/4

**EnVent Capital Markets Ltd.**

**Nominated Adviser (NOMAD)**

**Francesca Martino**

[fmartino@eventcapitalmarkets.co.uk](mailto:fmartino@eventcapitalmarkets.co.uk)

42 Berkeley Square - London W1J 5AW

Italian Branch, via Barberini n. 95 - 00187 Rome

Tel.: +39 06 896841

Fax: +39 06 89684155

KOLINPHARMA S.p.A.  
**SEDE OPERATIVA**  
Corso Europa, 5  
20020 Lainate (MI)  
Tel. +39 02 94324300  
Fax +39 02 93571446

**SEDE LEGALE**  
Via Larga, 8  
20122 Milano

[info@kolinpharma.com](mailto:info@kolinpharma.com)  
C.F. e P. IVA 08331990963  
Cap. soc. € 1.639.571 i.v.  
R.E.A. MI-2018304



[www.kolinpharma.com](http://www.kolinpharma.com)

